ENO2 and lung carcinoma: From the follow-up data of lung cancer patients, the survival curve analyses confirmed significant differences in Disease Free Survival (DFS) for patients with higher expression of YAP, TWIST1, SMAD3 and the level of NSE than those with lower expressions (P = 0.027, 0.011, 0.021, and 0.026, respectively).